Hybrigenics: the Ansel family enters the capital


(CercleFinance.com) – Hybrigenics announced yesterday evening that it had validated during its board of directors the agreement concluded between DMS Group and the Ansel family relating to the sale by DMS of 17% of its capital for the benefit of the family group.

This agreement seals the exchange of 2.08 million DMS shares held by the Ansel family group, i.e. 12.9% of the capital of DMS, against 46.54 million Hybrigenics shares held by DMS Group, i.e. 17% of the capital of Hybrigenics.

At the same time, the parties concluded a shareholders’ agreement organizing the governance of Hybrigenics around a six-member board of directors whose chairman will be Jean-Paul Ansel, the founder of DMS.

This strategic agreement is part of the continuity of the transformation announced at the end of 2022 aimed at consolidating the shareholding and governance in order to allow Hybrigenics to continue its development and to affirm its position in the pharmaceutical and biotechnology industry.

With this ‘significant’ investment, Jean-Paul Ansel says he wants to support the development of the company’s economic model towards the synergistic integration of innovative technologies and make it a ‘precursor’ in the value chain of the development of therapeutic treatments.

The title Hybrigenics climbed 5.8% on the Paris Stock Exchange on Wednesday following these announcements.

Copyright © 2023 CercleFinance.com. All rights reserved.

Did you like this article ? Share it with your friends with the buttons below.


Twitter


Facebook


LinkedIn


E-mail





Source link -85